Publications by authors named "C Stefanizzi"
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Hematol Oncol
August 2023
Article Synopsis
- Takezaki et al. found that patients with indolent lymphomas treated with Bendamustine plus Rituximab (BR) had similar outcomes whether they received four cycles or more, suggesting that fewer cycles could be sufficient.
- In a study involving 115 CLL patients, those who received at least 4 cycles of BR had better overall response rates and progression-free survival compared to those who only received 1-3 cycles, indicating that more treatment can be beneficial.
- Current practices suggest that for fit elderly CLL patients who achieve a complete response after 4 cycles, stopping treatment may be appropriate to reduce toxicity, especially with many alternative therapies now available.
The prognostic role of CD15 in acute myeloid leukemia (AML) has been tested in different studies with conflicting results. To address this issue, we retrospectively evaluated a cohort of 460 AML patients of all ages with the exclusion of acute promyelocytic leukemia (M/F 243/217, median age 50.6 years [range 0.
View Article and Find Full Text PDFThe occurrence of secondary hypogammaglobulinemia (SH) after chemo-immunotherapy represents a potential side effect in patients with indolent non-Hodgkin lymphomas (iNHL). Few data are available on SH occurring after chemotherapy and/or Rituximab (R). We retrospectively investigated the incidence and the risk factors for SH and infectious complications in patients with iNHL after chemo-immunotherapy.
View Article and Find Full Text PDFPotential clinical significance of CD34 expression in acute promyelocitic leukemia (APL) has not been deeply investigated. We hereby analyzed the clinico-biological features and treatment outcome of APL patients in relation to CD34 expression, even when expressed in a small subpopulation: 114 APL patients homogeneously treated with the AIDA schedule were included in the study and prognostic correlation with respect to CD34 expression, both when expressed in association with CD2 and as isolated expression (cutoff ≥2 to <10 % or ≥10 %), were investigated. CD34 was associated to CD2 in 30 patients and was isolated in 19 patients.
View Article and Find Full Text PDFWe report a case of a 54 year old patient with Multiple Myeloma (MM) and chronic HCV infection. In 2005 MM was diagnosed and a chemotherapy was prescribed. Before starting treatment a chronic HCV infection was found.
View Article and Find Full Text PDF